Funding for this research was provided by:
National Natural Science Foundation of China (NSFC 82071878)
Shanghai Anticancer Association FLIGHT PROJECT (SACA-AX-201903)
Shanghai Science and Technology Foundation (19DZ1930502)
Clinical Research Plan of SHDC (SHDC2020CR2008A)
Received: 7 December 2021
Accepted: 26 April 2022
First Online: 12 May 2022
: Institutional Review Board approval was obtained.
: Consent forms were obtained.The datasets generated during and/or analyzed during the current study are not publicly available due confidentiality but are available from the corresponding author on reasonable request.
: One of the coauthors (S.D.) is an employee of General Electric (GE) Healthcare (Shanghai, China). No other potential conflict of interest relevant to this article has been reported.